Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 22kWORD 19k
11 June 2019
E-001761/2019(ASW)
Answer given by Mr Andriukaitis on behalf of the European Commission
Question reference: E-001761/2019

As the Commission pointed out in its answer to the Written Question E-000138/2018, the European Centre for Disease Prevention and Control (ECDC) is currently updating the guidance on Human Papillomavirus (HPV) vaccines in order to cover specific related research questions and to specify the recommendations on options for their use.

A public consultation on this draft guidance(1) ended in April 2019. It focused on HPV vaccination of boys and of people living with human immunodeficiency viruses (HIV). The guidance aims to provide a comprehensive and systematic synthesis of the current knowledge and evidence around HPV vaccines. It seeks to support national decision making on HPV vaccine recommendations, taking into account the country context. The primary target audiences of this guidance are public authorities, national policymakers, entities responsible for the planning of healthcare and social support systems, staff working in national vaccination programmes and professional society organisations with an interest in HPV and/or immunisation programmes.

(1)https://ecdc.europa.eu/sites/portal/files/documents/hpv-public-consultation-1-April-2019.pdf

Last updated: 13 June 2019Legal notice